Cargando…

Diseases Linked to Polypharmacy in Elderly Patients

INTRODUCTION: Polypharmacy in several cases is deemed necessary and elderly patients are prone to this phenomenon. The objective of this study was to identify the prevalence and the predictors of polypharmacy among consecutively unplanned admissions of patients aged ≥65 years. PATIENTS AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Vrettos, Ioannis, Voukelatou, Panagiota, Katsoras, Apostolos, Theotoka, Despoina, Kalliakmanis, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757103/
https://www.ncbi.nlm.nih.gov/pubmed/29434639
http://dx.doi.org/10.1155/2017/4276047
_version_ 1783290803538362368
author Vrettos, Ioannis
Voukelatou, Panagiota
Katsoras, Apostolos
Theotoka, Despoina
Kalliakmanis, Andreas
author_facet Vrettos, Ioannis
Voukelatou, Panagiota
Katsoras, Apostolos
Theotoka, Despoina
Kalliakmanis, Andreas
author_sort Vrettos, Ioannis
collection PubMed
description INTRODUCTION: Polypharmacy in several cases is deemed necessary and elderly patients are prone to this phenomenon. The objective of this study was to identify the prevalence and the predictors of polypharmacy among consecutively unplanned admissions of patients aged ≥65 years. PATIENTS AND METHODS: In 310 patients (51% women), mean age 80.24 years (95% CI 79.35–81.10), demographic characteristics, medical history, medications, and cause of admission were recorded. Parametric tests and multiple logistic regression analysis were applied to identify the factors that have significant association with polypharmacy. RESULTS: 53.5% of patients belonged to polypharmacy group. In multivariate analysis the independent predictors of polypharmacy were arterial hypertension (p = 0.003, OR = 2.708, and 95% CI 1.400–5.238), coronary artery disease (p = 0.001, OR = 8.274, and 95% CI 3.161–21.656), heart failure (p = 0.030, OR = 4.042, and 95% CI 1.145–14.270), atrial fibrillation (p = 0.031, OR = 2.477, and 95% CI 1.086–5.648), diabetes mellitus (p = 0.010, OR = 2.390, and 95% CI 1.232–4.636), dementia (p = 0.001, OR = 4.637, and 95% CI 1.876–11.464), and COPD (p = 0.022, OR = 3.626, and 95% CI 1.208–10.891). CONCLUSIONS: Polypharmacy mainly was linked to cardiovascular diseases. If deprescribing is not feasible, physicians must oversee those patients in order to recognise early, possible drug reactions.
format Online
Article
Text
id pubmed-5757103
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-57571032018-02-12 Diseases Linked to Polypharmacy in Elderly Patients Vrettos, Ioannis Voukelatou, Panagiota Katsoras, Apostolos Theotoka, Despoina Kalliakmanis, Andreas Curr Gerontol Geriatr Res Research Article INTRODUCTION: Polypharmacy in several cases is deemed necessary and elderly patients are prone to this phenomenon. The objective of this study was to identify the prevalence and the predictors of polypharmacy among consecutively unplanned admissions of patients aged ≥65 years. PATIENTS AND METHODS: In 310 patients (51% women), mean age 80.24 years (95% CI 79.35–81.10), demographic characteristics, medical history, medications, and cause of admission were recorded. Parametric tests and multiple logistic regression analysis were applied to identify the factors that have significant association with polypharmacy. RESULTS: 53.5% of patients belonged to polypharmacy group. In multivariate analysis the independent predictors of polypharmacy were arterial hypertension (p = 0.003, OR = 2.708, and 95% CI 1.400–5.238), coronary artery disease (p = 0.001, OR = 8.274, and 95% CI 3.161–21.656), heart failure (p = 0.030, OR = 4.042, and 95% CI 1.145–14.270), atrial fibrillation (p = 0.031, OR = 2.477, and 95% CI 1.086–5.648), diabetes mellitus (p = 0.010, OR = 2.390, and 95% CI 1.232–4.636), dementia (p = 0.001, OR = 4.637, and 95% CI 1.876–11.464), and COPD (p = 0.022, OR = 3.626, and 95% CI 1.208–10.891). CONCLUSIONS: Polypharmacy mainly was linked to cardiovascular diseases. If deprescribing is not feasible, physicians must oversee those patients in order to recognise early, possible drug reactions. Hindawi 2017 2017-12-25 /pmc/articles/PMC5757103/ /pubmed/29434639 http://dx.doi.org/10.1155/2017/4276047 Text en Copyright © 2017 Ioannis Vrettos et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Vrettos, Ioannis
Voukelatou, Panagiota
Katsoras, Apostolos
Theotoka, Despoina
Kalliakmanis, Andreas
Diseases Linked to Polypharmacy in Elderly Patients
title Diseases Linked to Polypharmacy in Elderly Patients
title_full Diseases Linked to Polypharmacy in Elderly Patients
title_fullStr Diseases Linked to Polypharmacy in Elderly Patients
title_full_unstemmed Diseases Linked to Polypharmacy in Elderly Patients
title_short Diseases Linked to Polypharmacy in Elderly Patients
title_sort diseases linked to polypharmacy in elderly patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757103/
https://www.ncbi.nlm.nih.gov/pubmed/29434639
http://dx.doi.org/10.1155/2017/4276047
work_keys_str_mv AT vrettosioannis diseaseslinkedtopolypharmacyinelderlypatients
AT voukelatoupanagiota diseaseslinkedtopolypharmacyinelderlypatients
AT katsorasapostolos diseaseslinkedtopolypharmacyinelderlypatients
AT theotokadespoina diseaseslinkedtopolypharmacyinelderlypatients
AT kalliakmanisandreas diseaseslinkedtopolypharmacyinelderlypatients